OUR VIEW · OPINION中文

Viking: our view and what our model says about 2030

By · AI-assisted, human-reviewed and edited · · 7 sources · Fact-checked · 9 min read (37 min with all details)

Our view

Viking is a single-asset bet on VK2735, a weekly GIP/GLP-1 injection (the same drug class as Lilly's Zepbound) that also comes as a daily pill. The drug works; the open questions are whether a small company can sell a fourth- or fifth-to-market obesity drug into a price war run by Lilly and Novo, and how many more shares it will issue on the way. At $24.40 the price asks for less than an on-time approval with an average Phase 3 profile, and on our inputs about six runs in ten beat the hurdle. The result turns mainly on approval by 2030, on how good the Phase 3 profile is, and on whether a buyer appears.

Price, Oct 23 close
$24.40
Hurdle, end-2030
$35
Median value, end-2030
$48
P10–P90 range, end-2030
$3.5–$130
Simulations beating hurdle
62%
End below today's price
29%

Prices: closing price, Oct 23, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean

Market data as of the Oct 23, 2026 close ($24.40). The hurdle and the probabilities depend on that price. Values per share at Dec 31, 2030, undiscounted, from 50,000 simulations.

Snapshot at the Oct 23, 2026 close

Cash and investments
$502M
Enterprise value
$2.3B
Cash use per quarter
$105M
Price/sales
n/m
P/E
n/m

Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Jul 29, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $24.40. n/m = not meaningful (e.g. negative earnings).

Earlier versions

VersionPrice usedHorizonMedian valueP10–P90Beat chance
Oct 29, 2026THIS VERSION $24.4 (Oct 23, 2026) end-2030$48$3.5–$13062%

No earlier versions yet. Each row is frozen as published: when we update this view, the previous numbers stay here.

Version 1.28 · Oct 29, 2026

Editors hold this stock.

Prepared Oct 25, 2026. Market data as of the Oct 23, 2026 close ($24.40); market value about $3.1B on 127.5M shares at Sep 30, 2026). Viking reported Q3 2026 on Oct 28 (results release) and filed its Q3 10-Q on Oct 29. Cash and share figures are updated to Sep 30, 2026, and the simulation is re-anchored on the Q3 10-Q; market data are unchanged.

Filings used and labels

Latest filings: 10-K for FY2025 (Feb 11, 2026), 10-Qs for Q1 and Q2 2026 (Apr 30, Jul 29, 2026), proxy (Apr 1, 2026), offering documents (Sep 23–28, 2026), Forms 4 to Aug 7, 2026 (none filed since, through Oct 23).

Labels used below: Fact (filings, trial registries or market data), Company (management claims), Analyst (named or consensus views), Our view (our own reasoning). Each section ends with a confidence level.

Simulation result (value per share at Dec 31, 2030, undiscounted; 50,000 simulations):

  • P10 $3.5 · P50 $48 · P90 $130 (middle half $19–$86; mean $60).
  • Hurdle $35 (the end-2030 price that earns 9% a year from today): 62% of simulations beat it (about +18% a year at the median); 29% end below today’s price.
  • Takeovers are included: about a quarter of runs end in a sale, mostly after a positive Phase 3. Without them the median is $42, still above the hurdle.

What would move the result

  • Approval of the injection by 2030 (in ~85% of runs): if approved, the median would move to about $57; if not, to about $3.
  • The Phase 3 profile (78-week weight loss and dropouts; weak in 27%, in line in 43%, strong in 22% of runs): the median would move to about $24 with a weak profile, $58 in line and $106 strong.
  • Peak sales (analysts’ ~$6.5B in 2035 used in 45% of runs, our ~$3.3B in 55%): on our view alone the median would move to about $37; on analysts’ story alone, to about $63.
  • The discount rate after 2030 (11%, for a single-drug launch): at 9%, the median would move to about $50.
  • A partner or a takeover (partner in ~32% of runs; takeover at the small/mid biotech base rate in 24% of runs, included): with a partner in every successful run, the median would move to about $50; standalone with no takeover, to about $42.

Our view in brief

  • The drug works. VK2735 gave about 18% weight loss at 21 weeks, and patients switched to monthly shots kept up to 90% of it. Phase 3 injection data are due in H2 2027, with a likely launch in 2029.
  • It arrives late, into a price war. It would be the fourth or fifth obesity drug of its kind, after Lilly’s retatrutide (about 28% weight loss) has raised the bar and net prices have fallen toward $150–450 a month.
  • Funded to the data, not the launch. $960M of cash and short-term investments at Sep 30, after the $575M September raise. Expect more share sales or a partner before launch.
  • Value turns on approval. The market values the whole pipeline at about $2.4B after net cash. Our middle outcome is $48 against a $35 hurdle (middle half $19–$86, mean $60); 62% of runs beat it and 29% lose money.
  • Governance flags: rewritten CEO performance goals, about 70% say-on-pay support, and a buyback approved eight weeks before a discounted share sale.
  • Watch the Q3 10-Q, CagriSema’s FDA decision and the retatrutide filing, the VANQUISH topline (H2 2027) and any partner or bid.

1. The business in one paragraph

Viking has no revenue, and almost all of its value rests on one drug it owns outright, VK2735, so our model is a single-drug launch model with small add-ons for the rest of the pipeline. The add-ons are the oral form of VK2735, the maintenance dose and VK3019, plus VK2809 (MASH) as a small option valued separately. Ligand terminated the VK2809 licence in May 2026 and sued, and Viking’s challenge is unresolved (Ligand 8-K, Apr 24, 2026; Viking cross-complaint, Jul 2, 2026). We put the chance that Viking keeps or recovers the rights at 25% and the chance of a successful partnered Phase 3 at 40%, worth about $0.7B ($0.4–1.2B) at end-2030 after Ligand’s royalties and milestones: roughly $0.5 a share at those odds. The full facts are in Viking’s Long View → /stocks/vktx/long-view/

Confidence: high.

2. Where growth comes from (3–5 years)

All value to 2030 depends on VK2735 winning approval around 2029 and taking a small slice of a very large, fast-cheapening market. In our model that means the Phase 3 result, the approval date and the net price per patient decide almost everything; we expect a newcomer in 2029 to net roughly $3,000–4,500 a year per patient. Management has kept its trial timelines, with two small slips, so we take its 2027 data timing at face value.

The facts behind this

Nothing is on sale today, so “growth” here means launch.

What has to happen, in order:

  • VANQUISH-1 (about 4,500 adults with obesity) and VANQUISH-2 (about 1,000 with type 2 diabetes) report positive 78-week results in H2 2027. The doses are 7.5, 12.5 and 17.5 mg weekly against placebo (Fact). Then comes a filing (our estimate: H1 2028) and approval (our estimate: H1 2029).
  • The label and data need to stand out. The September 2026 maintenance study is the best evidence so far. Weight loss kept rising through 33 weeks of weekly dosing. Patients switched to every-other-week or monthly shots kept most of their loss (see table). Company: no other dual or triple agonist is currently available in both formulations.
  • The tablet (SUNRISE-1 and -2, 560 patients each, 68 weeks; primary completion Jul and Oct 2028) would add a second product around 2030. Company: it would be “the first dual agonist” pill approved.
Key VK2735 data (Fact, company releases) Result Caveat
Phase 2 VENTURE, weekly injection, 13 weeks (Feb 2024) Up to 14.7% weight loss from baseline Short
Maintenance study, induction, 21 weeks (Sep 2026) 16–19% across doses (17.8% at 17.5 mg, n=118) Phase 1; healthy obese adults
Weekly 17.5 mg continued to week 33 21.7%, no plateau n=13
Switch to every-other-week, weeks 21–33 Up to 97% of loss kept (placebo 61%) 12 weeks only; n=12–13 per arm
Switch to monthly, weeks 21–33 Up to 90% of loss kept Same; side effects similar to placebo
Phase 2 VENTURE-Oral, tablet, 13 weeks (Aug 2025) Up to 12.2% High dropout; stock fell about 40% that day

Size of the market. Independent estimates disagree widely. One syndicated report (ResearchAndMarkets, Oct 2026) puts the global anti-obesity drug market at $45.8B in 2025 and $148.6B by 2034. Our view: the yardstick that matters is price, not volume. US net prices are converging toward $150–450 a month. Medicare pays a net $245 a month for Wegovy and Zepbound under the GLP-1 Bridge (from Jul 1, 2026), and Lilly’s Foundayo pill sells for $149–349 a month to cash payers (press reports; medium confidence). A newcomer in 2029 should plan on roughly $3,000–4,500 a year net per patient.

Consensus path and fallback. Viking has no revenue consensus we can see: StockAnalysis shows revenue estimates as unavailable, and EPS consensus of −$4.59 for 2026 (17 analysts) and −$4.34 for 2027 (analyst count paywalled). Long-range (2028–30) consensus is not public to us. Fallback: our own patients × net price build; the simulation (section 7) mixes it with the analysts’ figures that are visible (about $1.3–1.5B of 2030 sales and $6.5B in 2035, unadjusted for failure risk).

Track record (Fact). Viking gives no financial guidance beyond cash runway: “into 2028” (Company, Q2 call, Jul 29, 2026). The 10-Q’s formal statement moved from “through at least September 30, 2027” (Q2) to “through at least December 31, 2027” (Q3, after the September raises). Product timelines have mostly held, with two small slips; VK2809 is the weak spot.

Timelines against guidance:

  • VANQUISH-1 enrolled by November 2025 and VANQUISH-2 in Q1 2026, both as promised.
  • The VK3019 filing was on time. Its Phase 1 started Jul 6, 2026 (registry), a few days after the Q2 guidance, though the company described it as a Q2 start.
  • Slip: the maintenance data moved from “mid-2026” (Oct 2025) to Q3 2026, and still arrived on Sep 22.
  • Slip: the oral Phase 3 start moved from Q3 to Q4 2026; it was announced Oct 14, but ClinicalTrials.gov shows it not yet recruiting.
  • Against the record: VK2809 never found the partner management sought from 2024, and Ligand now alleges a lack of diligence on it.

Reliance on unapproved drugs, in place of backlog (Our view): total. All of Viking’s value depends on drugs that are not yet approved, and about 90% of it on VK2735.

Confidence: medium (efficacy data are early and small; no long-range consensus).

3. The edge (moat)

VK2735’s edge is flexibility, not strength. It looks roughly as potent as tirzepatide, comes as both a shot and a pill, and may allow monthly maintenance dosing. But Lilly’s triple agonist retatrutide (about 28% weight loss) has raised the efficacy bar, and the incumbents control price, supply and payers; in our model that edge shows up as share in the in-line and strong profile runs, not as pricing power.

The facts behind this

Why it could win (Company/Our view):

  • One molecule in three formats: a weekly shot to lose weight, a less frequent shot or a daily pill to keep it off. Switching patients between unrelated drugs is what the maintenance study argues against.
  • Cost of goods (Our view). A peptide made at multi-ton scale under a dedicated CordenPharma contract (capacity for 100M autoinjectors and over 1B tablets a year; Fact) should allow cash-pay pricing.
  • Patents to 2042–45 nominal (Fact, 10-K) and no royalties owed.

Why it may not:

  • It reaches market late. Tirzepatide, semaglutide (injection and pill) and orforglipron are approved, CagriSema has an FDA decision due in Q4 2026, and retatrutide is to be filed in Q1 2027.
  • No commercial partner. Viking has only just hired a chief commercial officer (Q1 2026).
  • The market is treating small obesity entrants harshly. Structure Therapeutics, whose oral GLP-1 started Phase 3 in August, has a market value of $1.5B against $1.34B of cash (EV about $0.2B, Oct 23).

Competition by drug (Fact unless marked; cross-trial comparisons are rough)

Drug Company Type and dosing Status, Oct 2026 Weight loss (trial, time)
Zepbound/Mounjaro (tirzepatide) Lilly GIP/GLP-1, weekly shot Approved; self-pay $299–449/month ~21% at 72 wks (SURMOUNT-1)
Wegovy (semaglutide) Novo GLP-1, weekly shot; daily pill (approved Dec 2025) Approved; Medicare negotiated price from 2027 ~15% at 68 wks (STEP-1)
Foundayo (orforglipron) Lilly Small-molecule daily pill FDA approved Apr 1, 2026; EU CHMP positive Oct 16, 2026 (press; not confirmed by the EMA) ~12% at 72 wks (ATTAIN-1)
Retatrutide Lilly GIP/GLP-1/glucagon, weekly Five positive Phase 3s; filing Q1 2027 28.3% at 80 wks (TRIUMPH-1)
CagriSema Novo GLP-1 + amylin, weekly FDA decision Q4 2026 (company) 22.7% at 68 wks; lost head-to-head vs tirzepatide (20.2% vs 23.6%)
MariTide Amgen Monthly antibody-peptide Phase 3; data 2027 Up to ~20% at 52 wks (Phase 2)
PF-08653944 (ex-Metsera) Pfizer Monthly GLP-1 shot Phase 3 starting 2026; data ~2028 Up to 12.3% placebo-adjusted at 28 wks (Phase 2b VESPER-3, weekly-to-monthly switch); up to 14.1% (VESPER-1, weekly)
Aleniglipron Structure Daily oral small molecule Phase 3 from Aug 2026 16.3% placebo-adjusted at 44 wks
Petrelintide Zealand/Roche Amylin, weekly Phase 3 start H2 2026 10.7% from baseline at 42 wks (placebo 1.7%)
VK2735 shot / pill Viking GIP/GLP-1 weekly; monthly maintenance; daily pill Phase 3 / Phase 3 starting 17.8% from baseline at 21 wks (17.7% placebo-adjusted; shot); 12.2% at 13 wks (pill)

Competitor-readout calendar

When Event Why it matters for Viking
Q4 2026 CagriSema FDA decision (Novo) Another weekly option with a tolerability story
~Dec 2026 TRIUMPH-5, retatrutide vs tirzepatide, completes Sets the efficacy bar VK2735 will be judged against
Late 2026 Orforglipron EU decision; aleniglipron OLE data (ObesityWeek, Nov) Pill competition for oral VK2735
Q1 2027 Retatrutide filing (Lilly) Approval ~2028, a year before VK2735
Jan 1, 2027 Semaglutide Medicare negotiated price takes effect ($274/month, CMS) Anchors Medicare pricing
2027 MariTide Phase 3 readouts (Amgen) Monthly dosing, Viking’s maintenance pitch
2028 Pfizer monthly GLP-1 Phase 3; aleniglipron Phase 3 More entrants at VK2735’s launch
2026–27 Semaglutide generics outside the US (Canada, India, China, Brazil) Price pressure ex-US (medium confidence)

Confidence: medium.

4. The worst realistic risk

The worst realistic case is commercial, not clinical: VANQUISH succeeds, but VK2735 launches in 2029 into a market where retatrutide sets the efficacy bar and Lilly and Novo set prices near $250 a month. Viking then has to raise money at low prices to fund a launch it cannot win alone. A clinical or safety failure is less likely but would leave little more than cash. We think further share sales before launch are close to certain, and our model includes them: shares rise to about 209M by 2030. Cash should last through the VANQUISH data and filing but not a launch.

The facts behind this
Risk How likely (to 2030) How bad Notes
Commercially marginal launch (late, undifferentiated, no partner) Medium Severe Simulation: median about $24 with a weak trial profile
VANQUISH misses or a safety signal emerges Low (~8% in the simulation) Severe Simulation: median about $3 if VANQUISH fails
Further dilution before launch High Medium $449.8M left on the ATM; launch costs not funded
Price erosion (MFN deals, Medicare $245, $149 pills) High High Canaccord cut its target on this on Oct 20
Ligand wins the VK2809 dispute Medium Low VK2809 is only a small option in our valuation (about 10% odds)
Supply concentration (one manufacturer, European API sites) Low–medium Medium Tariff exposure if API comes from Corden’s Swiss and German sites (our view)

Legal and regulatory docket (Fact, 10-Q Q2 2026 and Ligand filings)

Matter Status Accrued Next date
Ligand v. Viking (San Diego Superior Court): Ligand says Viking breached diligence duties on the TR-β programme (VK2809, VK0214). Its termination notice (Apr 24, 2026; 10 days’ notice) took effect May 4, 2026, it says. It seeks damages and return of IP; on termination Viking must also grant Ligand a non-exclusive, low-single-digit-royalty licence to Viking-developed IP needed for TR-β products Complaint May 19, 2026; Viking cross-complaint against Ligand and its affiliate Metabasis Jul 2, 2026; Ligand’s demurrer against the cross-claims Aug 19, 2026; written discovery under way None Viking’s opposition due Feb 11, 2027; hearing Feb 26, 2027
Viking v. Ascletis (ITC trade secrets) ITC ruled for Viking (May 29, 2025), incl. sanctions; both sides appealed to the Federal Circuit; Ascletis brief filed Jun 15, 2026; Viking’s responsive brief Sep 25, 2026 None (possible gain) Oral argument expected Q4 2027
Viking v. Ascletis (S.D. Cal.) Stayed pending the ITC appeal None After the appeal

Dependence map

  • Licensor. Ligand: VK2809 and VK0214 royalties (low-to-mid single digits), development and regulatory milestones of up to $75M per indication (up to three indications) and up to $150M of sales milestones. VK2735 and VK3019 are not affected (Fact).
  • Manufacturer. CordenPharma is the only long-term supplier. Viking announced prepayments totalling $150M over 2025–28, credited against future orders (release, Mar 11, 2025); the schedule by year is not disclosed (Fact).
  • Payers (Our view). Medicare covers obesity drugs only through price deals struck with Lilly and Novo. A newcomer would need its own deal. Commercial insurers and PBMs gate access, and cash-pay channels (LillyDirect, NovoCare, TrumpRx, telehealth) set the floor price.
  • Regulator. FDA timelines (the 10-K flags the 2025–26 shutdowns and FDA staffing cuts).
  • People. Founder-CEO Brian Lian since 2014; CMO Hubert Chen joined in Q2 2026.

Product-programme delays vs plan (Fact)

Programme Plan Status
VANQUISH-1/-2 enrolment End-2025 / Q1 2026 Done Nov 2025 / Mar 2026
Maintenance data Mid-2026, then Q3 2026 Delivered Sep 22, 2026
Oral Phase 3 start Q3 2026, then Q4 2026 Announced Oct 14; first patients Nov 2026 (registry)
VANQUISH extension studies Late 2026 / early 2027 Start expected 1Q27; results expected 2028 (Q3 release)
VK3019 Phase 1 Q2 2026 Started Jul 2026 (registry); single-dose study to complete in Q4 2026, then a 4-week multiple-dose study from 1Q27 (Q3 release)

Survival check: passes until about the VANQUISH data, not until launch.

  • Cash (Fact, Q3 release): $959.8M of cash, cash equivalents and short-term investments at Sep 30, 2026, up from $501.7M at Jun 30 (excluding restricted cash at both dates) after $596.5M of net proceeds from the September offerings and Aug–Sep ATM sales (offering documents). Q3 operating cash use was $138.2M (Fact, Q3 10-Q: $377.3M for the nine months less $239.1M in H1). Against that sit $258.75M of 2% convertible notes due October 2032 (carried at $250.7M).
  • Burn (Fact, 10-Qs and Q3 release). Operating cash burn was $377M in the first nine months of 2026: $138M in Q3, $125M in Q2 and $114M in Q1. In Q3, R&D rose to $166.8M (Q2: $115.8M), its highest quarter so far, and the net loss to $183.2M (Q2: $128.0M).
  • Runway guidance: “into 2028” (Company, Q2 call); the 10-Q says “at least Sep 30, 2027”, both before the raise. After it (Q3 release, Oct 28): cash provides “the runway needed to reach important milestones, including completion of the company’s ongoing Phase 3 obesity trials”, which Viking expects in 2027. The Q3 10-Q (Oct 29) now says “through at least December 31, 2027”.
  • Our view: at about $450–550M a year, cash lasts into H2 2028, through the VANQUISH readout and filing but not a launch. Viking could get through a bad year without raising money; it cannot launch without raising money or finding a partner.

Confidence: medium–high.

5. Financial quality (read the notes)

The accounts are simple and clean: no revenue, no adjusted metrics, and a balance sheet that is mostly cash. The quality questions are about burn, the CordenPharma prepayments and how capital is raised; the share count, about 127.5M today and about 140M with every option and the notes, feeds directly into our per-share values. The full facts are in Viking’s Long View → /stocks/vktx/long-view/

The facts behind this

Latest half-year (H1 2026, 10-Q for Q2 2026 filed Jul 29, 2026) and trailing 12 months to Jun 30, 2026, with FY2024–25 from the 10-K (filed Feb 11, 2026); events after Jun 30 from the offering documents (424B5 and term sheet, Sep 23–25; 8-K Sep 28, 2026) and Forms 4.

Sources: 2024 and 2025 from the 10-K; H1 2026 from the Q2 2026 10-Q; TTM is our sum (FY2025 less H1 2025 plus H1 2026, using the 10-Q comparatives).

2024 2025 H1 2026 TTM Jun 2026
R&D ($M) 101.6 345.0 265.9 509
Operating loss ($M) 150.9 393.3 296.7 560
Net loss ($M) 110.0 359.6 286.3 535
Operating cash burn ($M) 87.8 278.7 239.1 418
Stock-based pay ($M) 29.7 40.8 21.5 37

Standard checks (pre-revenue version):

  1. Revenue and margins. Not applicable; there are no product or partner revenues.
  2. Burn trend. R&D was $150M in Q1 2026 and $116M in Q2 as VANQUISH enrolment finished (10-Qs Q1 and Q2 2026), then rose to $167M in Q3; Viking attributed the year-on-year rise to clinical studies, manufacturing, stock pay, salaries and consultants (Q3 release). Company (Q2 call): spending tapers in 2027. The oral Phase 3 is about 75% smaller than VANQUISH (our view, from registry enrolment).
  3. Working capital funding the burn. Payables and accruals rose by $33M in H1 2026 (to $69.0M and $40.5M; Q2 2026 10-Q balance sheet). The cash burn of $239M was therefore below the expense line, and the gap may reverse.
  4. Stock pay vs burn. Stock pay is about 9% of the TTM cash burn (our calculation from the table above), modest for the sector. PRSUs are booked with cumulative catch-ups when milestones become “probable” (10-Q notes), so stock-pay expense is lumpy.
  5. “Adjusted” definitions. None; Viking reports GAAP only (8-K earnings releases).
  6. Estimate catch-ups. Performance goals on the CEO’s 2014 restricted stock were replaced twice in 2025, adding $5.5M of incremental fair value under ASC 718 (proxy, Apr 1, 2026); the FY2025 10-K reports $4.5M of expense recognized for these restricted shares in 2025. The goals being replaced had been set in 2024. Only 183,095 shares are affected (10-Q Note 5; see section 8).
  7. Capitalised costs and commitments. R&D costs are expensed as incurred; the balance sheet includes prepayments and lease right-of-use assets. The CordenPharma prepayments ($150M in total over 2025–28 per the Mar 11, 2025 release; schedule by year not disclosed) are a real cash call (10-K and 10-Q); prepaid assets rose only $6M in H1 (Q2 2026 10-Q).
  8. Goodwill vs equity. No goodwill. Equity was $408M at Jun 30 (Q2 2026 10-Q; about $666M pro forma before the over-allotment, per the 424B5 capitalisation table), against a $1.13B accumulated deficit (10-Q).
  9. Material weaknesses and auditor (10-K FY2025). None. CBIZ CPAs (successor to Marcum) gave a clean controls opinion; its critical audit matter is clinical-trial accruals. Our view: a small audit firm for a $3B company, but no red flags.
  10. Policy changes. None material (10-K, 10-Qs).
  11. Receivable sales, factoring, royalty deals. None (10-K, 10-Qs). There are no royalty-monetisation or synthetic-royalty deals.
  12. One-offs in TTM. None; no milestones were received or paid (10-K, 10-Qs). Interest income ($33.7M in 2025 per the 10-K; $10.3M in H1 2026 per the 10-Q, about $20M annualised) cushions the net loss and will rise with the new cash.
  13. Capital allocation consistency. The board replaced an unused buyback with a larger one in July, then sold stock at a discount in September; nothing has been bought back.
    • In July 2026 the board terminated the unused $250M programme from February 2025 and approved a $500M buyback over three years, effective Jul 30, 2026 (10-Q Note 9). No shares have ever been repurchased under either programme.
    • On Jul 29 it also signed a new $500M ATM, with the prospectus filed with the Jul 30 S-3ASR. Viking sold 1.48M ATM shares in Aug–Sep ($48.7M net; 424B5).
    • It then raised approximately $575M gross in September: $316.25M from shares at $35 and $258.75M from convertible notes, including full exercise of both over-allotment options (Sep 28, 2026 8-K): 16% below the Sep 23 close, or 14% below the Sep 22 close cited in the prospectus.
    • Our view: the buyback was signalling, not a plan; the 2025 programme was never used either.
  14. Convertible notes (Fact; 8-K Sep 28, 2026, indenture, and pricing term sheet). $258.75M, 2% coupon, conversion price $50.75 (45% premium). Viking can provisionally call them from Oct 22, 2029 if the stock exceeds 130% of the conversion price (initially about $65.98) on at least 20 of the preceding 30 trading days and on the trading day immediately before notice, subject to the indenture’s other conditions. A takeover at $35 would add up to 8.9 shares per $1,000 of notes (make-whole). Book value is principal less issuance costs (about $251M; our estimate from the offering’s net proceeds). Fair value is not yet reported; Our view: it is probably below par after the share-price fall. The Q3 10-Q will show both.

Share-count bridge (Fact: Q2 2026 10-Q for Jun 30 shares and awards; 424B5 for the ATM and offering; Forms 4 for the Jul 28 vesting; our count where marked)

Layer Shares (M) Note
Basic, Jun 30, 2026 116.65 One class of stock; no warrants
+ ATM sales, Aug 5–Sep 14 +1.48 $48.7M net
+ September offering (incl. over-allotment) +9.04 At $35
+ PRSU vesting, Jul 28 +0.285 285,001 shares issued to three executives; tax-cover market sales do not reduce shares outstanding
= Basic, Sep 30, 2026 127.52 Q3 release: 127,521,229 shares; about 0.07M beyond the layers above, source not yet disclosed
+ Options (5.99M, average strike $17.83) +1.6 Treasury method at $24.40; 6.0M gross
+ RSUs and PRSUs +1.5 Jun 30 pool of 1.81M less the Jul 28 vesting
= Hypothetical diluted shares at $24.40 ~130.6 Using the pooled option approximation
+ Convertible notes +5.1 Out of the money; up to 7.4M on a make-whole
= Pro forma, all-in ~140.1 (gross options) Before $449.8M of unused ATM capacity

Dilution: shares rose about 11% in 2026, from 114.8M (Dec 31, 2025; 10-K) to 127.5M (Sep 30, 2026; Q3 release). 9.5M shares remained available in the equity plan reserve at Jun 30, 2026 (September 424B5).

Confidence: high on facts, medium on the Q3 cash-use estimate (pending the 10-Q).

6. Valuation today

The market values VK2735, the oral version, VK3019 and the rest at about $2.4B after net cash. That is less than a quarter of what Pfizer paid for Metsera’s earlier-stage programme a year ago, and it says investors doubt small obesity entrants can make money. Our model disagrees: its middle outcome at end-2030 ($48) sits well above the $35 the price needs to earn 9% a year, so today’s price implies less than an on-time approval with an average profile plus the dilution needed to fund the launch.

The facts behind this

Our calculation: market value $3.11B (127.5M × $24.40) minus $0.96B of cash and short-term investments at Sep 30 (Q3 release) plus $0.26B convertible notes gives an EV of about $2.4B. Earnings and sales multiples do not apply.

Company or deal Value What it bought or holds
Viking (Oct 23 close) Market value $3.1B; EV ~$2.4B Phase 3 GIP/GLP-1 shot + pill
Structure Therapeutics (Oct 23) Market value $1.5B; EV ~$0.2B Oral GLP-1 entering Phase 3
Eli Lilly (Oct 23) $1.14T; 14.8× TTM sales; 33× fwd P/E The market leader
Pfizer–Metsera (Nov 2025) ~$10B incl. CVR, after a bidding war with Novo Phase 2 monthly GLP-1
Novo–Akero (Oct 2025) Up to $5.2B Phase 3 MASH drug
Roche–Zealand petrelintide (Mar 2025) $1.65B upfront, up to $5.3B Phase 2 amylin (licence)

Market data: StockAnalysis, Oct 23–25, 2026. Deal values: company releases and press (medium confidence on CVR-inclusive figures).

Against its own history: the stock peaked near $99 in early 2024. It fell about 40% on the oral Phase 2 data in August 2025 and ended 2025 at about $35. On Sep 22, 2026 it jumped 36% to $40.85 on the maintenance data. It has since fallen 40% to a 52-week low, under the weight of the offering at $35, sector price worries and a parallel slide in other small obesity names. We found no single company-specific cause for the October fall.

Runs that beat the hurdle are mostly those with approval by 2030 and an in-line or strong profile; runs with a weak profile or no approval almost never do.

Analyst views. Consensus is Strong Buy: 21 analysts (S&P Global via StockAnalysis) give 14 Strong Buy, 5 Buy, 2 Hold and no Sell. The average 12-month target is $95 (median $95, range $38–125). Targets four times the price imply peak sales of several billion dollars, a takeover, or both. Short interest is 22.8% of the float (StockAnalysis, on the pre-offering float).

Other consensus sources and recent analyst actions:

  • MarketBeat shows “Moderate Buy” with one Sell and a $99 average; the gap comes from differences in coverage and window.
  • On the cautious side, the lowest target in the S&P Global set is $38 (most recently a Citi Neutral; Goldman initiated at Neutral, $30, in 2025).
  • Canaccord (Edward Nash, Buy) cut its target to $106 from $114 on Oct 20, citing lower obesity pricing from cash-pay programmes and MFN deals, which it says is “largely offset by growing overall market size” (as reported by Investing.com).
  • Other October actions: UBS initiated at Buy, $94, and H.C. Wainwright reiterated Buy, $102 (both Oct 14); Truist trimmed to $85 from $87 and Maxim reiterated Buy, $70 (both Oct 7).

Confidence: medium.

7. Value at end-2030: simulation

The simulation gives better than even odds of beating the hurdle (about six in ten): a middle outcome well above it, a long upside tail if VK2735 is approved with a good profile, and near-total loss if it is not. These figures show the spread our inputs imply, not a forecast.

Method: Valued at maturity (about 2035) and discounted back to end-2030 at 11%. At maturity: 3.9× (P25–P75 3.0–5.1×) next-year sales around 2035.

Implied end-2030 multiple: our end-2030 value implies 7.1× (P25–P75 4.5–11.5×) 2031 sales; today: no sales yet. A P/E is not shown: next-year earnings are positive in only 52% of runs.

Peer cross-check: comparable companies’ multiples give 4.3× (P25–P75 3.1–5.9×) 2031 sales at end-2030; not used for the value.

The result (end-2030 value per share): P25 / P50 / P75 of $19 / $48 / $86 (mean $60); 62% of runs beat the 9%-a-year hurdle and 29% end below today’s price. P10 and P90 are in the Our view box at the top.

The top five assumptions:

  1. Trial and approval: VANQUISH reads out in H2 2027, then a filing (our estimate: H1 2028) and approval (our estimate: around 2029). We put the chance of success well above the 57.8% industry average for Phase 3, because the mechanism is the same as tirzepatide’s.
  2. Peak sales: about $3.3B with an average profile on our view, against analysts’ about $6.5B in 2035; 55% of runs follow ours and 45% theirs, weights set from forecast track records.
  3. Net price: roughly $3,000–4,500 a year per patient for a 2029 newcomer, as US net prices converge toward $150–450 a month.
  4. Value at maturity: each run is valued around 2035 at about 3.8–4.1 times next-year sales, the multiple comparable US biotechs have traded at for a drug near its peak, and discounted back to the end of 2030 at 11% a year.
  5. Takeovers and financing: takeovers arrive at the base rate for US biotechs of $1–15B, twice as likely after a positive Phase 3; Viking otherwise funds its launch by selling shares.

The most influential events (effects in the Our view box at the top): approval of the injection by 2030; the Phase 3 profile class (weak, in line or strong); a VANQUISH failure or class safety signal; a takeover; and a co-commercialisation partner.

Sensitivities (P50; chance of beating the hurdle):

  • Alternative method (not our main): valued directly at end-2030 at a launch-phase multiple of early-launch peers (about 8× 2031 sales, P10–P90 3.5–10×) instead of at maturity: $45 (59%). It is lower because 2031 sales are still early in the launch; the maturity method credits the ramp to 2035.
  • Our view only, with no analyst mix: $37 (52%).
  • Discount rate 9% instead of 11%: $50 (63%).
  • A partner in every successful run: $50 (64%).
  • Standalone, no takeover (the main result includes takeovers in 24% of runs): $42 (56%).
How the simulation is built, the hurdle result and the result without add-ons

How the value is set (one sentence): because Viking has no sales yet, each run is projected to about 2035, when VK2735’s sales should have matured, valued there at the sales multiple that comparable US biotechs have traded at for similar growth (about 3.8–4.1 times next-year sales for a drug near its peak), and that value plus the cash earned on the way is discounted back to the end of 2030 at 11% a year.

  • Each run plays out, quarter by quarter to 2030, the Phase 3 result, the profile class, the approval date, a possible partner, a possible takeover (at the base rate for US biotechs of $1–15B, twice as likely after a positive Phase 3), financing and competitor events.
  • It then projects sales to about 2035 and values the company there at a peer sales multiple for its growth at that point. The result is discounted back to the end of 2030 at 11% a year.
  • Where our peak-sales view (about $3.3B with an average profile) differs from analysts’ (about $6.5B in 2035), 55% of runs follow ours and 45% theirs, weights set from forecast track records.
End-2030 value per share P10 P25 P50 (middle) P75 P90 Mean Beats 9%/yr Below today
Without explicit add-ons (launch parts, pipeline options; same simulation) $0.0 $11.4 $39 $82 $128 $54 53% 37%

P25 and P75 bound the middle half of runs; P10 and P90 are the tails. Values are at Dec 31, 2030 and are not discounted to today.

Hurdle result (takeovers included, as for all small and mid-size biotechs): the median is about $13.01 above the $35 hurdle and about six runs in ten (62%) beat it, so the price gives a moderate margin of safety. It asks for an on-time approval with at least an average profile; Viking on its own, with no buyer, still lands above the hurdle ($42); takeovers add about $6 to the median, so only that part of the margin rests on a sale that nobody has offered in nearly three years of public data. The upside comes from the strong-profile and analyst-view runs, and the downside from a weak profile, a trial failure or heavy dilution. Interim path: in about one run in five the implied value falls below half of today’s price at some quarter-end before 2030.

Confidence: the arithmetic is reproducible; the inputs are low–medium confidence. Peak sales and the trial profile are the softest numbers.

8. Management and governance

Management has delivered trials on time and raised money well, but pay rewards activity rather than value, and goalposts have moved. Insiders hold meaningful stock and have barely sold beyond tax withholding. In our model, management’s record supports taking the trial timelines at face value, while the September raise is the pattern we expect to repeat before launch.

The facts behind this
  • Team (Fact). Brian Lian, PhD, founder-CEO since 2014; CFO Greg Zante; COO Marianne Mancini, who announced her retirement on Feb 10, 2026 (effective Apr 30), then rescinded it on Apr 27, 2026 and stays on under her 2015 agreement (Q1 10-Q); CCO Neil Aubuchon (2026); CMO Hubert Chen (Q2 2026). Board additions: Dorothy Gemmell (ex-GoodRx president, commercial), Jul 2026.
  • Credibility events (Fact). Trial enrolment and data timing have been met, with small slips. On the negative side, the September offering came the day after the data jump. It was priced 16% below the Sep 23 close (14% below the Sep 22 close cited in the prospectus), eight weeks after the board approved a $500M buyback, which replaced an unused $250M programme. The COO’s retirement and its reversal (Feb–Apr 2026) is a minor stability flag. The Ligand dispute alleges neglect of VK2809.
  • What pay rewards (Fact, proxy). CEO 2025 pay was $21.3M. Bonuses and PRSUs pay on operating milestones; nothing rewards trial results, approvals or share price over time, and the goals on an old CEO award have been reset three times in about two years. Our view: the plan pays for activity, and rewriting old goals to fit new plans weakens the link to value.

The CEO’s rewritten 2014 award and the 2025 bonus:

  • 2025 pay included $5.5M of incremental value ($5,174,613 + $309,960; ASC 718 fair value, not cash) from replacing the performance goals on 2014 restricted stock twice in 2025 (May and October).

  • The goals being replaced had themselves been set in 2024, and the company said they concerned objectives it “was no longer pursuing”. The company’s stated reason was “to provide additional incentives toward achieving the Company’s long-term plans”.

  • Mitigating context (10-Q Note 5): only 183,095 shares are affected (about $4.5M at $24.40). 62,252 vested in Jul 2025 and 90,633 by Jun 30, 2026. The remaining 30,210 are deemed improbable to vest.

  • The 2025 bonus paid at 92.5% of target on operating milestones: trial starts, enrolment, supply contracts and a financing above a threshold. PRSUs vest on milestones.

  • Shareholder pushback (Fact, May 19, 2026). Say-on-pay passed with about 70% of votes cast. Director Kathryn Rouan was re-elected with about 51%, and J. Matthew Singleton with 66%.

  • Insider activity, Oct 2025–Oct 2026 (Fact, 19 Forms 4). Almost all sales were tax withholding on vesting. Our view: timing is not suspicious, and the CEO still holds about 2.57M shares (about $63M).

Sales, purchases and the CEO’s trading plan:

  • Tax withholding on vesting: the CEO about $14M, the CFO and COO about $3M each.

  • Two directors sold after option exercises: Charles Rowland $2.13M (Oct 27, 2025) and Matthew Foehr 16,000 shares, about $0.56M (Jan 2, 2026).

  • The CCO bought $150K in the open market (Mar 2026).

  • The CEO adopted a trading plan on Jan 15, 2026 to sell up to 365,000 shares by Dec 31, 2026, eight months before the maintenance data. No later Form 4 filings were found through Oct 29, so no plan sales had been reported. Q3 insider sales were only tax withholding on vesting: 187,951 shares (about $6.3M) by the CEO, CFO and departing COO on Jul 29. A director, Charles Rowland, adopted a trading plan on Sep 4, 2026 to sell up to 128,000 shares by Dec 7, 2027 (Q3 10-Q).

  • Voting control (Fact). One share class, no controlling holder, 66% of shares held by institutions and a staggered board (three classes).

Confidence: high on facts, medium on interpretation.

9. Signposts

The decisive signpost is the VANQUISH topline in H2 2027; before then, Q3 cash, competitor approvals and pricing, and any partner or bid matter most.

Eight signposts: what on track and broken look like
# Signpost On track Broken When
1 Q3 2026 results Cash ≈ $0.95–1.0B; runway extended into 2029; Corden prepayment schedule disclosed Runway not extended; new commitments Reported Oct 28, 2026: cash $960M; runway stated as reaching completion of the Phase 3 obesity trials. 10-Q (Oct 29): “through at least December 31, 2027”; Corden prepayments paid over 2026–2028, schedule still not disclosed
2 Oral Phase 3 (SUNRISE) first patients; VK3019 single-dose data Dosing starts Nov 2026; clean VK3019 safety Slippage into 2027 Nov 2026–early 2027
3 Competitor events: CagriSema FDA decision, TRIUMPH-5, retatrutide filing Nothing that leaves no room for a fourth weekly incretin Retatrutide approval pulled forward; price cuts below ~$200/month Q4 2026–Q1 2027
4 Ligand case Settlement or early ruling for Viking Loss of VK2809 plus damages 2027 (no date)
5 Oral maintenance study (Part 2) Pill maintains most of the loss Pill fails to maintain loss 2027 (company); registry completion May 2027
6 VANQUISH-1/-2 topline (78 wks) Top dose ≥ ~20% placebo-adjusted; AE discontinuations ≤ ~10% < ~17%, high dropout, or any safety signal H2 2027
7 Partnership, financing or bid Partner funds the launch, or a bid Large raise below $25 Any time; most likely after VANQUISH
8 Filing and approval Filing H1 2028; approval ~2029 Complete response letter or delay 2028–29

10. Open questions

  • Will Viking launch alone, partner, or sell? If alone, through which channels (cash-pay, telehealth, employers)?
  • What weight loss and dropout rate will VANQUISH show at 78 weeks?
  • Can a newcomer get Medicare coverage outside the Lilly/Novo price deals, and at what net price?
Five more open questions
  • When are the remaining CordenPharma prepayments ($150M in total) due, and how large are any minimum-purchase obligations?
  • What weight loss and dropout rate will VANQUISH show at 78 weeks? Is 17.5 mg a high enough top dose when the maintenance study went to 22.5 mg?
  • Why replace an unused $250M buyback with a $500M one in July, then sell stock at a discount in September?
  • What exactly does Ligand claim, and is VK2809 worth defending?
  • Where does Corden make the API (US or EU), and what is the tariff exposure?
  • What are the analysts’ peak-sales assumptions behind the average 12-month target of $95? We could not see them.

Pipeline and catalysts (biotech module)

For VK2735 the scientific risk is low and the commercial risk high; the side programmes carry little or no value in our numbers.

The pipeline table and success-rate benchmarks

The benchmarks are industry averages by phase. “Our view” adjusts for how well validated the mechanism is; for VK2735 the scientific risk is low and the commercial risk high.

Programme Indication Phase Next readout / date Benchmark PoS* Our view
VK2735 shot (VANQUISH-1, ~4,500 pts) Obesity 3 Primary completion Jul 1, 2027; topline H2 2027 57.8% (Ph3→filing) Well above (~85–90%): same mechanism as tirzepatide; risk is profile, not efficacy
VK2735 shot (VANQUISH-2, ~1,000–1,100 pts) Obesity + type 2 diabetes 3 Same 57.8% Same
VK2735 shot, filing → approval Obesity — Our estimate: filing H1 2028, approval ~2029 90.6% (filing→approval) Around benchmark
VK2735 pill (SUNRISE-1/-2, 560 pts each) Obesity; obesity + T2D 3 Start Nov 2026; primary completion Jul / Oct 2028 57.8% Above (~75%) on efficacy; tolerability is the risk
VK2735 maintenance Part 2 (~195–270 pts) Maintenance (pill, monthly and every-other-week shots) 1 2027 (registry: May 2027) n/a Supports label and positioning
VK3019 (amylin/calcitonin) Obesity 1 Single-dose study completing Q4 2026; 4-week multiple-dose study from 1Q27 (Q3 release) 52.0% (Ph1→Ph2) Around benchmark; crowded class
VK2809 (THR-β) MASH 2b done No Phase 3; licence disputed 28.9% (Ph2→Ph3) Small option: about 10% odds × ~$0.7B
VK0214 X-ALD 1b done Out-licensing sought; licence disputed — Zero
VK5211 (SARM) Hip-fracture recovery 2 done Out-licensing sought — Zero

*BIO/Informa/QLS, Clinical Development Success Rates 2011–2020: Phase 1→2 52.0%, Phase 2→3 28.9%, Phase 3→filing 57.8%, filing→approval 90.6%. Citeline 2014–2023: Phase 3 55.0%.

Exclusivity and policy exposure (Fact unless marked)

Patents and exclusivity run far beyond 2030, so pricing policy, not generic competition, is the exposure that matters for our model.

The facts behind this
Item VK2735 Comment
Patents 13 issued, 113 pending (GLP-1 agonist family); nominal expiry 2042–45 Owned; no royalties
Regulatory exclusivity New chemical entity: 5 years from approval (~2029–34) Generic filings (Paragraph IV) possible from year 4 (~2033) (Our view)
Patent-term extension Up to 5 years, capped at 14 years after approval Probably not needed given 2042+ expiry (Our view)
Loss of exclusivity Late 2030s–2040s (Our view) Far beyond FY2030
Medicare negotiation (IRA) As an NDA peptide, treated like semaglutide (small-molecule clock): eligible 7 years after approval, price applies at 9 years, ~2038 (Our view) Semaglutide’s negotiated price ($274/month) applies from 2027
Medicare Part B vs D Part D (self-administered) Medicare obesity coverage today only via Lilly/Novo deals (GLP-1 Bridge, $245 net, $50 copay)
MFN pricing No Viking deal disclosed Lilly and Novo deals (Nov 2025) set MFN-linked prices; new launches expected at international parity (Our view)
Gross-to-net Not priced yet Incumbent list prices ~$1,000–1,350/month vs net ~$250–500: discounts of 60–80% (Our estimate from public prices)

Five-line summary
  1. Viking is a pre-revenue, single-asset bet on VK2735, a GIP/GLP-1 weekly shot and daily pill, with Phase 3 data in H2 2027 and a likely 2029 launch.
  2. The drug works (about 18% weight loss at 21 weeks, monthly maintenance holding up to 90%), but it will arrive fourth or fifth into a market where Lilly sets both the efficacy bar (retatrutide about 28%) and prices ($149–450 a month).
  3. Cash was $960M at Sep 30 after a $575M September raise (stock at $35 plus 2% notes due 2032), enough to reach the data but not to fund a launch. Expect more dilution or a partner. The Ligand dispute threatens VK2809 only.
  4. At $24.40 (EV about $2.4B), our simulation puts the end-2030 middle outcome at $48 a share (P25–P75 $19–$86, mean $60) against a $35 hurdle: 62% of runs beat it and 29% lose money. Approval by 2030 and the Phase 3 profile decide most of it.
  5. Watch the Q3 10-Q, competitor events (CagriSema decision, retatrutide filing), VANQUISH topline in H2 2027 and any partner or bid. Governance flags: rewritten CEO performance goals and about 70% say-on-pay support.

Sources

Sources (accessed Oct 25, 2026): 25 filings, releases and data sources
  • Viking 10-K FY2025 (Feb 11, 2026)
  • 10-Qs Q1 and Q2 2026 (Apr 30, Jul 29, 2026)
  • 8-K earnings releases Q3 2025, Q4 2025, Q1, Q2 and Q3 2026 (Q3: Oct 28, 2026)
  • 8-K Sep 22, 2026 (maintenance study)
  • 8-K Sep 28, 2026 (offerings, indenture)
  • 424B5 prospectus supplements and pricing term sheet (Sep 23–25, 2026)
  • S-3ASR (Jul 30, 2026)
  • DEF 14A (Apr 1, 2026) and 8-K May 26, 2026 (meeting results)
  • Forms 4 Oct 2025–Aug 2026 (SEC EDGAR)
  • Viking press releases Oct 6, 14 and 21, 2026
  • ClinicalTrials.gov (NCT07104500, NCT07104383, NCT07868835, NCT07868939, NCT07838740, NCT07846033)
  • Ligand 8-K (event Apr 24, filed Apr 30, 2026) and 10-Q Q1 2026
  • Q2 2026 call transcript (Investing.com)
  • StockAnalysis (VKTX price history, statistics, forecast; GPCR and LLY statistics, Oct 23 close)
  • Investing.com (Canaccord note, Oct 20, 2026; 52-week low, Oct 23)
  • 24/7 Wall St. (Sep 24, 2026)
  • ad-hoc-news (Oct 2026)
  • Motley Fool (Aug 30, 2026)
  • Simply Wall St via Yahoo Finance (Oct 13, 2026)
  • MarketBeat consensus
  • Lilly, Novo, Pfizer, Amgen, Structure, Zealand/Roche releases and press coverage (AJMC, PharmExec, BioPharma Dive, MedCity News, GlobeNewswire) on orforglipron, retatrutide, CagriSema, MariTide, PF-08653944, aleniglipron, petrelintide
  • CMS and press coverage on the Medicare GLP-1 Bridge and TrumpRx prices
  • ResearchAndMarkets (Oct 14, 2026)
  • Pfizer–Metsera, Novo–Akero and Roche–Zealand deal coverage (Zacks, STAT, GEN)
  • BIO/Informa/QLS (2021) and Citeline success-rate studies

About Viking Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

Disclosure: one or more of our editors own shares of companies named in this article (VKTX) as a long-term investment. For education only, not investment advice. Full disclaimer.

Spot an error or have a question? · Corrections policy